Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Russano M, et al. Among authors: chiari r. Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31. Cancer Immunol Immunother. 2022. PMID: 34462870 Free PMC article.
Primary and metastatic brain tumors.
Franceschi E, Scopece L, Gori S, Chiari R, Crino L. Franceschi E, et al. Among authors: chiari r. Forum (Genova). 2006;14(1):E2. Forum (Genova). 2006. PMID: 16873085
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: chiari r. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F. Marchetti A, et al. Among authors: chiari r. J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643. J Thorac Oncol. 2015. PMID: 26295376 Free article.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Barni S, et al. Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19. Lung Cancer. 2015. PMID: 26314614 Free article.
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L. Chiari R, et al. Lung Cancer. 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. Epub 2015 Sep 14. Lung Cancer. 2015. PMID: 26395848
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Metro G, et al. Among authors: chiari r. Expert Opin Pharmacother. 2015;16(17):2601-13. doi: 10.1517/14656566.2015.1094056. Epub 2015 Oct 6. Expert Opin Pharmacother. 2015. PMID: 26439599
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Cappuzzo F, et al. Among authors: chiari r. Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565910 Clinical Trial.
205 results